Investors
Overview
Havn Life is focused on the rapidly growing field of psychedelic medicine. We have the opportunity to lead the standardization of psychedelic supply to shift human performance & mental health paradigms.
- DEFINED ROUTE TO NATURAL HEALTH PRODUCTS MARKET.
- PRODUCT FORMULATION OF EFFECTIVE MICRODOSING OF NOVEL PSYCHOACTIVE COMPOUNDS.
- MANAGEMENT TEAM WITH EXTENSIVE CLINICAL & NHP PRODUCT DEVELOPMENT EXPERIENCE.
- DEVELOPING STATE-OF-THE-ART MYCOLOGY LAB FOR PSYCHEDELIC EXTRACTION.
- PARTNERSHIP WITH CANADIAN VETERANS FOR PHASE 1 PRE-CLINICAL RESEARCH.
- RECEIVED FIRST HEALTH CANADA LICENSE IN 2020.
Our Team
Collaboration across disciplines
Creating positive patient experiences and mental health outcomes
Vic Neufeld
Executive Chairman
CEO of Aphria for 5 years during large scale build up to one of the leading cannabis producers in the world.
Tim Moore
Chief Executive Officer
Former CEO of Green Growth Brands, from IPO through to Jan 2019, leading the Company to ~$1 Billion market cap.
Gary Leong
Chief Scientific Officer
Former Chief Scientific Officer at Aphria Inc. where he established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs & Research and Development functions.
Eli Dusenbury
Chief Financial Officer
Served as a consultant for audit and public practice firms in both Canada and the US and has held CFO positions for publicly traded companies.
Dr. Ivan Casselman
Chief Psychedelic Officer
Extensive nutraceutical formulation experience, with several products available in legal cannabis markets in North America.
Alexzander Samuelsson
Chief Research Officer
Lead chemist of a publicly traded extraction company, Alexzander developed intellectual property and patented methods in the extraction of cannabis oils.
Jenna Pozar
Chief Operations Officer
18 years of NHP marketing and logistics experience, including Jamieson Wellness and Body Plus. Responsible for the growth and planning for 200+ retail store accounts and three national chains, with a portfolio of eight natural health and performance brands.
Juliana Mollica
Director of Innovation and Quality Assurance
Led projects as the quality assurance and compliance manager for cannabis and pharmaceutical companies to ensure maintenance of GMP requirements, developing QMS for multi-site projects, compliance training programs, and increasing compliance and quality rates.
Rick Brar
Vice Chairman
CEO & Chairman of Brains Bioceutical Corp. A global manufacturer and distributor of Cannabinoid API.
Tim Laidler
Director
Executive Director of the Institute for Veterans Education and Transition at UBC. The institute focuses on supporting the needs of veterans in the community as well as supporting cutting edge research with Veterans.
Dennis Staudt
Director
Financial and business expert. As CPA with 22 years as a partner in PricewaterhouseCooper's Audit and Assurance Group. Vice-President of a family-owned farming operation, Staudt Farms.
Allan Oberman
Advisor
Served as CEO for Concordia International, an international speciality pharmaceutical company with sales in 90 countries and over 200 medicines.
Sheila Copps
Advisor
The Honourable Sheila Copps was the first woman to ever hold the position of Deputy Prime Minister and served for ten years in the federal cabinet.
Dr. David Mokler
Advisor
Expert specialist in neuropharmacology, psychopharmacology, substance abuse, drug abuse, brain development, dopamine and serotonin including work relevant to the 5HT2a receptors in psychedelics
David King
Advisor
Drug science and policy expert who received the Dr Abbas Khan Medal by King’s College London for ‘outstanding humanitarian contributions to the service of society’. Also Founder of the Breaking Convention, Europe’s largest academic conference on psychedelic drug research.
Consultants
Legal Counsel
Cassels
cassels.com
Auditor
De Visser Gray LLP
devissergray.com
Transfer Agent
Odyssey Trust Company
odysseytrust.com
CORPORATE PRESENTATION
Or listen to a recorded investor presentation from our CEO, Tim Moore. Email required.